
A new multidisciplinary pilot trial will screen participants for IL-6-linked methylation markers, aiming to administer targeted epigenetic inhibitors while embedding longitudinal assessments of mood and cognition. This initiative leverages findings that IL-6-driven methylation can serve as both diagnostic tools and therapeutic targets for improving outcomes in prenatal depression, prevalent in 7–9% of expectant mothers. By integrating immunometabolic and mental health data, the trial supports a precision-medicine approach that could redefine treatment protocols for at-risk populations.
“Collectively, these enrichments pointed to a shared DNAm signature underlying IL-6 and a spectrum of inflammatory comorbidities, supporting the utility of IL-6–associated CpGs as potential biomarkers of health.”